Syntekabio Presents Nonclinical Data of immuno-oncologic agent...
DAEJEON, South Korea, May 15, 2020 /PRNewswire-AsiaNet/ -- - STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect.- Triple combination therapy of STB-C017, PD-1, CTLA-4 immu...
Authors: LATEST ASIANET NEWS RELEASES